Systematic review / meta-analysis / 1989
Epogam (evening primrose oil) significantly improved atopic eczema symptoms, particularly itch, in a meta-analysis of controlled trials.
Nine controlled trials (four parallel, five cross-over) in eight centres evaluated Epogam (evening primrose oil containing gamma-linolenic acid) for atopic eczema. In parallel studies, both patient and doctor scores demonstrated a highly significant improvement over baseline (P < 0.0001) due to Epogam and were significantly better than placebo. Cross-over trials showed similar results, though the doctors' global score difference favoured Epogam but missed significance. Pruritus showed no placebo response but a substantial, highly significant response to Epogam (P < 0.0001), and clinical improvement positively correlated with increases in plasma dihomogammalinolenic and arachidonic acids.
- Study type
- Meta-analysis of 9 controlled trials (4 parallel, 5 cross-over)
- Who was studied
- Patients with atopic eczema across nine controlled trials in eight centres
- What was measured
- Severity of eczema (inflammation, dryness, scaliness, pruritus, overall involvement)
THE PAPER
Meta-analysis of placebo-controlled studies of the efficacy of Epogam in the treatment of atopic eczema. Relationship between plasma essential fatty acid changes and clinical response.
Morse PF, Horrobin DF, Manku MS, Stewart JC, Allen R, Littlewood S, Wright S, Burton J, Gould DJ, Holt PJ. Br J Dermatol, 1989.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.